Design and Evaluation of Promethazine Hydrochloride Rapimelts

Authors

  • R. Panner Selvam T John College of Pharmacy
  • M. P. Gowrav
  • Vineeth Chandy

DOI:

https://doi.org/10.37591/(rrjops).v10i1.450

Abstract

Objective: In the present study, efforts were taken to develop rapimelts of promethazine HCl—
an antiemetic agent with an objective to achieve rapid disintegration, and further improve the
bioavailability of drug.Methods:Rapimelts were prepared by direct compression method
using superdisintegrants such as crospovidone (cp), croscarmellose sodium (ccs), sodium
starch glycolate (ssg). The prepared formulations were evaluated for precompression
parameters such as bulk density, tapped density, Carr’s compressibility, Hausner ratio and
angle of repose. The prepared batches of rapimelts of promethazine HCl were evaluated for
hardness, weight variation, thickness, friability, drug content, disintegration time, wetting
time, water absorption ratio, andin vitrodissolution profile.Results: From the Fourier
Transform Infrared Spectroscopy (FTIR) studies, the compatibility of drug-polymers was
confirmed. All the rapimelts were shown satisfactory results which complies with official
limits. Among the prepared nine formulations, the formulation containing 7.5% crospovidone
(PF9) showed highest drug release of 98.6% than other formulations.Conclusion:From this
study we can conclude that formulated rapimelts of promethazine HCl containing
crospovidone are better and effective than conventional tablets to meet patient compliance
and give fast relief from vomiting and emesis.
Keywords: Promethazine HCl, rapimelts, superdisintegrant

Cite this Article
Selvam RP, Gowrav MP, Chandy V.
Design and Evaluation of Promethazine
Hydrochloride Rapimelts. Research &
Reviews: A Journal of Pharmaceutical
Science. 2019; 10(1): 11–19p.

 

References

Kumari S, Sharad V, kumar SP, Kumar YR. Fast dissolving drug delivery system: review article. J Pharma Res. 2010; 3(6): 1444-1449p.

Yadav G, kapoor A, Bhargava S. Fast dissolving tablets recent advantages: a review. Int J Pharm Sci Res 2012; 3(3): 728 -736p.

Deepak S, Kumar D, Singh M, Singh G, Rathore MS. Fast disintegrating tablets: a new era in novel drug delivery system and new market opportunities. J Drug Delivery & Ther 2012; 2(3): 74-86.

Hannan PA, Khan JA, Khan A, Safiullah S. Oral dispersible system: A new approach in drug delivery system. Indian J Pharm Sci 2016; 78(1): 2-7.

Mohammadi H, Kumar VH. Formulation and evaluation of solid dispersion incorporated fast disintegrating tablets of tenoxicam using design of experiment. Int J Pharma Sci Drug Res 2019; 11(1): 35-44.

Rahane1 RD, Rachh PR. A review on fast dissolving tablet. J Drug Deliv & Ther 2018; 8(5): 50-55.

Kiranpreet K, Rajeev G. Fast dissolving tablet-an innovative approach. indo american j pharma sci 2018; 05(10): 10603-10611.

https://www.drugbank.ca/drugs/DB01069.

Mulagada S, Baratam SR. Design and evaluation of ondansetron fast disintegrating tablets using natural polymers and modified starches as super disintegrants for the enhancement of dissolution. J Young Pharm 2017; 9(4): 519-524

Manimaran V, Damodharan N. Development of fast dissolving tablets of nisoldipine by solid dispersion technology using poloxamer 407 and poloxamer 188. J Young Pharm 2016; 8(4): 341-9.

Rajpurohit H, Sharma P, Sharma S, Purohit S, Bhandari A. Hordeum vulgare hull in the design of fast disintegrating tablets. J Young Pharm 2011; 3(3): 211-5.

Kingeori LD, Walker RB. The use of response surface methodology to evaluate the impact of level 2 SUPAC-IR Changes on the in vitro release of metronidazole and ranitidine from a fixed-dose combination tablet. Dissolution Technologies 2012; 28-36p.

Bayrak Z, Tas C, Tasdemir U. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Eur J Pharm Biopharm. 2011; 78: 499-505p.

Padmaja B, Ramakrishna R, Sravani S. formulation and evaluation of fast dissolving tablets of captopril. J Pharm Res 2014; 8(7): 963-968.

Downloads

Published

2019-06-01

Issue

Vol. 10 No. 1 (2019)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.